Management of Pulmonary Langerhans Cell Histiocytosis

Diagnostic Approach

High-resolution CT (HRCT) scan is essential for diagnosis, typically showing characteristic peribronchiolar nodular infiltrates combined with irregularly shaped cystic spaces in an upper and mid-lung distribution with costophrenic angle sparing 1, 2
Bronchoalveolar lavage (BAL) can be diagnostic if CD1a-stained cells exceed 5% 1
Bronchoscopic or surgical lung biopsy provides definitive diagnosis by demonstrating Langerhans cells within inflammatory infiltrates 2

Smoking cessation is the cornerstone of treatment and may result in clinical improvement in approximately 33% of patients 1, 2, 3
Systemic corticosteroids are used for patients with significant symptoms or progressive disease 1, 2
Monitor diffusing capacity (DLCO), which is frequently reduced in PLCH 3

The American Thoracic Society notes that the course of pulmonary Langerhans cell histiocytosis is variable and unpredictable, ranging from asymptomatic presentation to progressive respiratory failure 1, 2
Most patients with pulmonary histiocytosis X suffer persistent or progressive disease, with death due to respiratory failure occurring in approximately 10% of patients 3
Patients with multifocal and extranodal disease tend to have a less favorable prognosis 4

First response assessment should be carried out within 4 months of initiating treatment, according to the American Society of Hematology 4
If disease stabilizes or enters remission, surveillance intervals can be extended to 6-12 months 4